KR102597462B1 - 항-phf-타우 항체 및 이의 용도 - Google Patents

항-phf-타우 항체 및 이의 용도 Download PDF

Info

Publication number
KR102597462B1
KR102597462B1 KR1020197028728A KR20197028728A KR102597462B1 KR 102597462 B1 KR102597462 B1 KR 102597462B1 KR 1020197028728 A KR1020197028728 A KR 1020197028728A KR 20197028728 A KR20197028728 A KR 20197028728A KR 102597462 B1 KR102597462 B1 KR 102597462B1
Authority
KR
South Korea
Prior art keywords
ser
gly
lys
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197028728A
Other languages
English (en)
Korean (ko)
Other versions
KR20190130133A (ko
Inventor
마르크 머르켄
토마스 말리아
마리안느 보르거스
콜렌 크리스토프 반
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Priority to KR1020237037321A priority Critical patent/KR102695287B1/ko
Publication of KR20190130133A publication Critical patent/KR20190130133A/ko
Application granted granted Critical
Publication of KR102597462B1 publication Critical patent/KR102597462B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197028728A 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도 Active KR102597462B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237037321A KR102695287B1 (ko) 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
US62/472,214 2017-03-16
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037321A Division KR102695287B1 (ko) 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20190130133A KR20190130133A (ko) 2019-11-21
KR102597462B1 true KR102597462B1 (ko) 2023-11-03

Family

ID=63521020

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197028728A Active KR102597462B1 (ko) 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도
KR1020237037321A Active KR102695287B1 (ko) 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237037321A Active KR102695287B1 (ko) 2017-03-16 2018-03-16 항-phf-타우 항체 및 이의 용도

Country Status (22)

Country Link
US (3) US10766953B2 (https=)
EP (1) EP3596119A4 (https=)
JP (3) JP7159185B2 (https=)
KR (2) KR102597462B1 (https=)
CN (2) CN117209599A (https=)
AR (1) AR111288A1 (https=)
AU (1) AU2018234709B2 (https=)
CA (1) CA3055598A1 (https=)
CL (1) CL2019002566A1 (https=)
EA (1) EA201992038A1 (https=)
IL (2) IL268700B2 (https=)
JO (1) JOP20180021A1 (https=)
MA (1) MA47789A (https=)
MX (2) MX2019010922A (https=)
MY (1) MY205672A (https=)
PH (1) PH12019501973A1 (https=)
SG (1) SG11201907754RA (https=)
TW (1) TWI771389B (https=)
UA (1) UA128385C2 (https=)
UY (2) UY37635A (https=)
WO (1) WO2018170351A1 (https=)
ZA (2) ZA202101318B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371376B2 (en) * 2011-12-20 2016-06-21 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
MX2021014473A (es) * 2019-05-31 2022-01-06 Lilly Co Eli Compuestos y metodos dirigidos a la tau humana.
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
MX2022012628A (es) * 2020-04-08 2023-01-11 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos.
CN116348769A (zh) * 2020-07-14 2023-06-27 詹森药业有限公司 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody
WO2022090158A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
WO2022176959A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
IL307170A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Anti-tau antibodies and their uses
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK0610330T3 (da) 1991-10-25 1998-01-26 Innogenetics Nv Monoklonale antistoffer mod microtubulus-associeret protein tau
DK0737208T3 (da) 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
EP0772634B1 (en) 1994-07-29 2003-03-12 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2057193B1 (en) 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
ES2826883T3 (es) 2009-10-14 2021-05-19 Janssen Biotech Inc Métodos de maduración por afinidad de anticuerpos
CN102884085B (zh) * 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
ES2548686T3 (es) 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Also Published As

Publication number Publication date
IL268700B2 (en) 2024-07-01
ZA202311412B (en) 2025-04-30
MA47789A (fr) 2020-01-22
BR122023021947A2 (pt) 2024-02-20
WO2018170351A1 (en) 2018-09-20
TWI771389B (zh) 2022-07-21
TW201900682A (zh) 2019-01-01
IL268700A (en) 2019-10-31
UY40829A (es) 2024-08-15
BR122023021958A2 (pt) 2024-02-20
IL268700B1 (en) 2024-03-01
IL310464A (en) 2024-03-01
CN110799531A (zh) 2020-02-14
PH12019501973A1 (en) 2020-06-29
AU2018234709A1 (en) 2019-08-29
KR102695287B1 (ko) 2024-08-13
KR20190130133A (ko) 2019-11-21
MY205672A (en) 2024-11-05
JP7159185B2 (ja) 2022-10-24
JP2024088689A (ja) 2024-07-02
US20210179696A1 (en) 2021-06-17
BR112019019049A2 (pt) 2020-04-22
JP2022191383A (ja) 2022-12-27
US20180265575A1 (en) 2018-09-20
MX2019010922A (es) 2019-11-08
JP2020513804A (ja) 2020-05-21
CN117209599A (zh) 2023-12-12
US20230047413A1 (en) 2023-02-16
UY37635A (es) 2018-09-28
CA3055598A1 (en) 2018-09-20
ZA202101318B (en) 2023-03-29
AR111288A1 (es) 2019-06-26
MX2024015440A (es) 2025-02-10
WO2018170351A8 (en) 2019-12-19
CL2019002566A1 (es) 2019-12-27
EA201992038A1 (ru) 2020-02-06
US11365244B2 (en) 2022-06-21
KR20230155025A (ko) 2023-11-09
UA128385C2 (uk) 2024-07-03
CN110799531B (zh) 2023-08-04
SG11201907754RA (en) 2019-09-27
AU2018234709B2 (en) 2024-10-31
EP3596119A4 (en) 2021-01-13
EP3596119A1 (en) 2020-01-22
US10766953B2 (en) 2020-09-08
JOP20180021A1 (ar) 2019-01-30

Similar Documents

Publication Publication Date Title
KR102597462B1 (ko) 항-phf-타우 항체 및 이의 용도
CN115697393A (zh) 抗PHF-tau抗体及其用途
KR20200130350A (ko) 항-phf-타우 항체 및 이의 용도
US20240150451A1 (en) Anti-tau antibodies and uses thereof
EA047298B1 (ru) Антитела к phf-тау и их применение
EA049614B1 (ru) Анти-псф-тау-антитела и способы их применения
BR112019019049B1 (pt) Anticorpos antiphf-tau, ácido nucleico isolado, vetor, e composição farmacêutica
BR122023021958B1 (pt) Anticorpos anti-phf-tau, composição farmacêutica, e método in vitro de produção dos referidos anticorpos
BR122023021947B1 (pt) Usos de anticorpos anti-phf-tau

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230421

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230729

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231030

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231030

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231030

End annual number: 3

Start annual number: 1

PG1601 Publication of registration